BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld Asia
Home
» Genable Gets $6.8M for Gene Therapy in Retinitis Pigmentosa
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Genable Gets $6.8M for Gene Therapy in Retinitis Pigmentosa
Nov. 16, 2011
By
Cormac Sheridan
No Comments
DUBLIN, Ireland – Genable Technologies Ltd. raised €5 million (US$6.8) million in a Series B financing round to take forward a mutation-independent gene therapy approach for treating an autosomal-dominant form of retinitis pigmentosa (RP).
BioWorld Asia